Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 87.01 USD 0.07% Market Closed
Market Cap: 4.2B USD
Have any thoughts about
Axsome Therapeutics Inc?
Write Note

Axsome Therapeutics Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Axsome Therapeutics Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Axsome Therapeutics Inc
NASDAQ:AXSM
Total Current Assets
$479.1m
CAGR 3-Years
61%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Current Assets
$53.2B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
-1%
Bristol-Myers Squibb Co
NYSE:BMY
Total Current Assets
$28.1B
CAGR 3-Years
-4%
CAGR 5-Years
-7%
CAGR 10-Years
7%
Pfizer Inc
NYSE:PFE
Total Current Assets
$37.8B
CAGR 3-Years
-13%
CAGR 5-Years
2%
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Total Current Assets
$40.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
2%
Eli Lilly and Co
NYSE:LLY
Total Current Assets
$31.4B
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
10%
No Stocks Found

Axsome Therapeutics Inc
Glance View

Market Cap
4.2B USD
Industry
Pharmaceuticals

Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.

AXSM Intrinsic Value
94.15 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Axsome Therapeutics Inc's Total Current Assets?
Total Current Assets
479.1m USD

Based on the financial report for Sep 30, 2024, Axsome Therapeutics Inc's Total Current Assets amounts to 479.1m USD.

What is Axsome Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
61%

Over the last year, the Total Current Assets growth was -6%. The average annual Total Current Assets growth rates for Axsome Therapeutics Inc have been 61% over the past three years , 61% over the past five years .

Back to Top